Publications by authors named "Maria Jesusa Banal-Silao"
Article Synopsis
- A study in six Asian countries evaluated the real-world impact of dienogest treatment on health-related quality of life (HRQoL) in women with endometriosis, enrolling 887 participants with endometriosis-associated pelvic pain (EAPP).
- Results indicated significant improvements in HRQoL scores, especially in pain levels and feelings of control, with the most significant changes observed at 6 and 24 months after starting treatment.
- While many patients and doctors expressed satisfaction with dienogest, common side effects included bleeding irregularities and amenorrhea, with nearly 40% experiencing treatment-emergent adverse events.
Background: Dienogest has been shown to substantially improve endometriosis-associated symptoms such as debilitating chronic pelvic pain, and in turn, health-related quality of life (HRQoL). To date, there is no data on patient-reported outcomes reflecting the real-world practice in Asia where endometriosis is a relevant health, social and economic burden. This non-interventional, multi-center, prospective study aims to investigate the influence of dienogest on HRQoL.
View Article and Find Full Text PDFObjective: To assess whether the combined oral contraceptive (COC) ethinylestradiol (EE) 20 μg/drospirenone 3 mg taken in a 24/4-day regimen (ie, 4-day hormone-free interval) is more effective than an EE 20 μg/desogestrel (DSG) 150 μg COC taken in a 21/7-day regimen (ie, 7-day hormone-free interval) in reducing hormone withdrawal-associated symptoms (HWAS).
Methods: This double-blind, randomized study (NLM identifier: NCT01076582) was conducted at 34 centers in 12 countries. Otherwise healthy women who experienced ≥2 HWAS of headache, pelvic pain, and/or bloating when using their current COCs in a 21/7-day regimen were recruited.